Ultra-Low-Dose Immunotherapy May Benefit Cancer Patients in Low-Resource Countries

(MedPage Today) -- CHICAGO-- Triple oral metronomic chemotherapy combined with ultra-low-dose immunotherapy (TMC-I) may be a promising first-line treatment for patients in low-resource countries with recurrent or metastatic head and neck squamous...